Asia Pacific Genetic Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Asia Pacific Genetic Testing Market Report is Segmented by Type (Carrier Testing, Diagnostic Testing, Newborn Screening, Predictive and Presymptomatic Testing, Prenatal Testing, Other Types), Disease (Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Thalassemia, Rare Diseases, Other Diseases), Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing), and Geography (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific). The Market values are Provided (in USD million) for the above segments.

Asia Pacific Genetic Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Asia Pacific Genetic Testing Market Size

View Global Report
Asia-Pacific Gen
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 4.87 Billion
Market Size (2030) USD 8.54 Billion
CAGR (2025 - 2030) 11.90 %

Major Players

Asia-Pacific Genetic Testing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Asia-Pacific Genetic Testing Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Asia Pacific Genetic Testing Market Analysis

The Asia-Pacific Genetic Testing Market size is estimated at USD 4.87 billion in 2025, and is expected to reach USD 8.54 billion by 2030, at a CAGR of 11.9% during the forecast period (2025-2030).

The COVID-19 pandemic is expected to have a significant impact on market growth. Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs, etc., the biotech entities are investigating SARs-Cov-2 at an unprecedented rate, and a considerable amount of funds are being put into the R&D. For instance, in May 2021, Sanofi, a French-based pharmaceutical giant and Britain's GSK reported the start of phase 3 of a clinical study for COVID vaccine across the world, with sites in the Asia-Pacific region too. The vaccine will be based on recombinant DNA technology.

A study titled, 'Genetic testing and serological screening for SARS-CoV-2 infection in a COVID-19 outbreak in a nursing facility in Japan', was published in March 2021 in BMC Infectious Diseases. The study found that thorough PCR testing, in combination with comprehensive and separate genetic tests, is critical for managing COVID-19 outbreaks in nursing facilities. Serological testing is also beneficial for tracing contacts, confirming the number of infected individuals, and authorizing the termination of the outbreak. Thus, these developments are expected to boost market growth.

Certain factors that are driving the market growth include a growing demand for personalized medicine and the increased application of genetic testing in oncology. The diagnostic and pharmaceuticals sector in the Asia-Pacific region has gained momentum, owing to speedy adoption and rising technological advancements. This has resulted in the adoption of personalized medicine across the region.

Use of genetic tests for breast cancer diagnosis is gaining momentum. Women with certain BRCA1 or BRCA2 gene variations ((both of which are inherited) have up to an 85 percent lifetime chance of developing breast cancer, compared to a 13 percent chance among the general female population. Women with harmful BRCA1 and BRCA2 mutations also have up to a 39 and 17 percent chance, respectively, of developing ovarian cancer, compared with a 1.3 percent chance among the general female population. Thus, BRCA1 and BRCA2 genetic tests can guide preventive measures, such as prophylactic surgery, chemoprevention, and more frequent mammography. Increase in prevalence of breast cancer across Asian countries is a cause of concern. According to Globacan 2020, the number of new breast cancer cases diagnosed in China alone was 416,371. Thus, the demand for genetic tests is increased due to a greater emphasis in medicine from reaction to diagnosis of the disease.

Asia Pacific Genetic Testing Industry Overview

The Asia-Pacific genetic testing market is highly competitive and consists of several major players. In terms of market share, a few major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new ingredients at lower prices. Companies like Abbott Laboratories Inc., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Genomic Health Inc., and Mapmygenome hold the substantial market share in the Asia-Pacific genetic testing market.

Asia Pacific Genetic Testing Market Leaders

  1. Abbott Laboratories

  2. Bio-Rad Laboratories Inc.

  3. Myriad Genetics, Inc.

  4. Genomic Health Inc.

  5. Mapmygenome

  6. *Disclaimer: Major Players sorted in no particular order
Asia-Pacific Gen
Need More Details on Market Players and Competiters?
Download PDF

Asia Pacific Genetic Testing Market News

In May 2021, Fulgent Genetics, Inc., announced that it had made an incremental strategic investment in FF Gene Biotech, a Chinese entity formed through a Joint Venture between Fulgent Genetics, Xilong Scientific and Fuzhou Jinqiang Investment Partnership (FJIP). FF Gene Biotech was founded to bring Fulgent Genetics' Next Generation Sequencing (NGS) capabilities to the Chinese genetic testing market.

In May 2020, Seoul-based genetic testing company 3billion announced launch of a service for rare genetic diseases, where it can examine genetic mutations and interpret resulting data at service fee of USD 699.

Asia Pacific Genetic Testing Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Emphasis on Early Disease Detection and Growing Demand for Personalized Medicine
    • 4.2.2 Increasing Application of Genetic Testing in Oncology
  • 4.3 Market Restraints
    • 4.3.1 High Costs of Genetic Testing
    • 4.3.2 Social and Ethical Implications of Genetic Testing
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Carrier Testing
    • 5.1.2 Diagnostic Testing
    • 5.1.3 Newborn Screening
    • 5.1.4 Predictive and Presymptomatic Testing
    • 5.1.5 Prenatal Testing
    • 5.1.6 Other Types
  • 5.2 By Disease
    • 5.2.1 Alzheimer's Disease
    • 5.2.2 Cancer
    • 5.2.3 Cystic Fibrosis
    • 5.2.4 Sickle Cell Anemia
    • 5.2.5 Thalassemia
    • 5.2.6 Rare Diseases
    • 5.2.7 Other Diseases
  • 5.3 By Technology
    • 5.3.1 Cytogenetic Testing
    • 5.3.2 Biochemical Testing
    • 5.3.3 Molecular Testing
  • 5.4 Geography
    • 5.4.1 China
    • 5.4.2 Japan
    • 5.4.3 India
    • 5.4.4 Australia
    • 5.4.5 South Korea
    • 5.4.6 Rest of Asia-Pacific

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Bio-Rad Laboratories Inc.
    • 6.1.3 Danaher Corporation (Cepheid)
    • 6.1.4 Genomic Health Inc.
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Illumina Inc.
    • 6.1.7 Mapmygenome
    • 6.1.8 Myriad Genetics Inc.
    • 6.1.9 Qiagen NV
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 Beijing Laso Biotechnology Co., Ltd.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Asia Pacific Genetic Testing Industry Segmentation

A genetic test is a test performed to identify the presence of a particular gene or set of genes, with a particular sequence of the genome. The genes can be identified either directly through sequencing or indirectly through various methods. Genetic testing practices are rapidly increasing in rare disease diagnostics and for personalized medicines, which is driving the growth of this market.

The Asia Pacific Genetic Testing Market is Segmented by Type (Carrier Testing, Diagnostic Testing, Newborn Screening, Predictive and Presymptomatic Testing, Prenatal Testing, Other Types), Disease (Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Thalassemia, Rare Diseases, Other Diseases), Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing), and Geography (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific). The report offers the value (in USD million) for the above segments.

By Type Carrier Testing
Diagnostic Testing
Newborn Screening
Predictive and Presymptomatic Testing
Prenatal Testing
Other Types
By Disease Alzheimer's Disease
Cancer
Cystic Fibrosis
Sickle Cell Anemia
Thalassemia
Rare Diseases
Other Diseases
By Technology Cytogenetic Testing
Biochemical Testing
Molecular Testing
Geography China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Need A Different Region or Segment?
Customize Now

Asia Pacific Genetic Testing Market Research FAQs

How big is the Asia-Pacific Genetic Testing Market?

The Asia-Pacific Genetic Testing Market size is expected to reach USD 4.87 billion in 2025 and grow at a CAGR of 11.90% to reach USD 8.54 billion by 2030.

What is the current Asia-Pacific Genetic Testing Market size?

In 2025, the Asia-Pacific Genetic Testing Market size is expected to reach USD 4.87 billion.

Who are the key players in Asia-Pacific Genetic Testing Market?

Abbott Laboratories, Bio-Rad Laboratories Inc., Myriad Genetics, Inc., Genomic Health Inc. and Mapmygenome are the major companies operating in the Asia-Pacific Genetic Testing Market.

What years does this Asia-Pacific Genetic Testing Market cover, and what was the market size in 2024?

In 2024, the Asia-Pacific Genetic Testing Market size was estimated at USD 4.29 billion. The report covers the Asia-Pacific Genetic Testing Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Asia-Pacific Genetic Testing Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Asia Pacific Genetic Testing Industry Report

Statistics for the 2025 Asia-Pacific Genetic Testing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Genetic Testing analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.